Gridlock Guy learns hard lesson on car care A faulty tire sensor leads to a flat tire, prompting reflection on how delayed maintenance can impact more than just the driver.

Add Yahoo as a preferred source to see more of our stories on Google. A faulty tire sensor leads to a flat tire, prompting reflection on how delayed maintenance can impact more than just the driver.

John Wilkerson, a Washington correspondent, is the author of D.C. Diagnosis, a twice-weekly newsletter about the politics and policy of health and medicine. John writes about the politics of health ...

In a major breakthrough, IBM revealed the world’s first semiconductor chip technology built on a sub-1 nanometer chipmaking process. For comparison, the process uses transistor features smaller than ...

Eli Lilly CEO David Ricks reveals a new Medicare GLP-1 bridge program, providing weight loss medications at $50 per month for eligible Part D patients. The program, beginning July 1, aims to enhance ...

Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to get the Chinese biotech to apply its drug discovery and early development capabilities to multiple ...

BRUSSELS, June 24 (Reuters) - Eli Lilly's (LLY.N), opens new tab orforglipron type-2 diabetes and obesity pill could launch in China as soon as later this year, an executive at the U.S. drugmaker told ...

June 24 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab will collaborate on experimental medicines with a unit of oncology-specialist Abbisko ‌Cayman (2256.HK), opens new tab, with ...

White House officials on Tuesday shot down a report speculating President Trump gained access to the retatrutide weight loss drug under the Food and Drug Administration’s (FDA) “compassionate use ...

Eli Lilly is already a market leader in the GLP-1 market, but its high valuation could limit future gains. Viking Therapeutics doesn't have an approved product just yet, but VK2735 has shown a lot of ...

Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.

When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the ...